000062037 001__ 62037
000062037 005__ 20200221144306.0
000062037 0247_ $$2doi$$a10.1515/cclm-2015-0304
000062037 0248_ $$2sideral$$a93432
000062037 037__ $$aART-2016-93432
000062037 041__ $$aeng
000062037 100__ $$0(orcid)0000-0002-9304-3709$$aLópez-Laval, I.$$uUniversidad de Zaragoza
000062037 245__ $$aCardiac troponin i release after a basketball match in elite, amateur and junior players
000062037 260__ $$c2016
000062037 5060_ $$aAccess copy available to the general public$$fUnrestricted
000062037 5203_ $$aBackground: Available scientific data related to cardiac troponin I (cTnI) release after intermittent exercise is limited. It is also of interest to determine what personal or environmental factors mediate the exercise-induced release of cTnI. This study had two objectives: 1) to examine the individual release of cTnI to a basketball match; and 2) to establish the influence of athlete status as well as biological age on cTnI release. Methods: Thirty-six basketball players (12 adult elite PBA]: 27.3±4.1 years, 12 adult amateur ABA]: 29.6±2.9 years, and 12 junior elite JBA]: 16.6±0.9 years) participated in a simulated basketball match with serial assessment of cTnI at rest, immediately post-and at 1, 3, 6, 12, and 24 h post-exercise. Results: The basketball match increased cTnI levels (pre: median range]; 0.006 0.001-0.026]; peak post: 0.024 0.004-0.244] µg/L; p=0.000), with substantial individual variability in peak values. PBA and JBA players showed higher baseline and post-exercise cTnI values than ABA (all p<0.05). Peak cTnI exceeded the upper reference limit (URL) in the 26% of players (3 PBA; 6 JBA). Conclusions: The current results suggest that intermittent exercise can promote the appearance of cTnI and that this is potentially mediated by athlete status.
000062037 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/DEP2010-16767
000062037 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000062037 590__ $$a3.432$$b2016
000062037 591__ $$aMEDICAL LABORATORY TECHNOLOGY$$b5 / 30 = 0.167$$c2016$$dQ1$$eT1
000062037 592__ $$a1.038$$b2016
000062037 593__ $$aBiochemistry (medical)$$c2016$$dQ1
000062037 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000062037 593__ $$aClinical Biochemistry$$c2016$$dQ2
000062037 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000062037 700__ $$0(orcid)0000-0003-2644-9386$$aLegaz-Arrese, A.$$uUniversidad de Zaragoza
000062037 700__ $$aGeorge, K.
000062037 700__ $$aServeto-Galindo, O.
000062037 700__ $$aGonzález-Rave, J. M.
000062037 700__ $$aReverter-Masia, J.
000062037 700__ $$aMunguía-Izquierdo, D.
000062037 7102_ $$11006$$2245$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Educación Física y Depor.
000062037 773__ $$g54, 2 (2016), 333-338$$pClin. chem. lab. med.$$tClinical Chemistry and Laboratory Medicine$$x1434-6621
000062037 8564_ $$s724025$$uhttps://zaguan.unizar.es/record/62037/files/texto_completo.pdf$$yVersión publicada
000062037 8564_ $$s119982$$uhttps://zaguan.unizar.es/record/62037/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000062037 909CO $$ooai:zaguan.unizar.es:62037$$particulos$$pdriver
000062037 951__ $$a2020-02-21-13:34:56
000062037 980__ $$aARTICLE